– USA, NJ – Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Gregory Mayes, Executive Vice President and Chief Operating Officer, has been elected to the Company’s Board of Directors.
“I am delighted that Greg has been elected to our Board of Directors,” said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. “I have had the pleasure of working with Greg for many years and, throughout his career, he has been a key contributor in helping drive the success of organizations. I know he will add value to the board as we continue to move forward with the important work Advaxis is doing to develop new treatments for cancer patients.”
Mr. Mayes joined Advaxis in October 2013, bringing with him more than 20 years of management experience in the pharmaceutical industry. Since joining Advaxis, he has been instrumental in executing on a successful turnaround strategy for the Company which has improved both its financial position and development pipeline. Mr. Mayes has been key to identifying and negotiating partnerships with the Advaxis Lm Technology™ including clinical collaborations with MedImmune and Merck. In addition, Mr. Mayes has helped cultivate a growing base of institutional shareholders.
Prior to Advaxis, Mr. Mayes held executive leadership positions with ImClone Systems, Eli Lilly and AstraZeneca Pharmaceuticals. While at ImClone, he was selected to lead the integration of ImClone with Eli Lilly and also supported the clinical development and commercialization of ERBITUX (cetuximab). While with Astra Zeneca, Mr. Mayes provided legal support for the development and commercialization of five approved oncology products. Mr. Mayes received his bachelor of science from Syracuse University and a juris doctorate from Temple University School of Law.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. The Lm Technology, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’ lead Lm Technology immunotherapy, axalimogene filolisbac, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.